Search results for "Recurrence"

showing 10 items of 1036 documents

Management and Outcomes of Patients with Isolated Superficial Vein Thrombosis under Real Life Conditions (INSIGHTS-SVT).

2021

Objective Management and outcomes of superficial vein thrombosis (SVT) are highly variable and not well described. Therefore, the INvestigating SIGnificant Health TrendS in the management of SVT (INSIGHTS-SVT) study collected prospective data under real life conditions. Methods Prospective observational study of objectively confirmed acute isolated SVT. The primary outcome was a composite of symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), and extension or recurrence of SVT at three months. The primary safety outcome was clinically relevant bleeding. Results A total of 1 150 patients were included (mean age 60.2 ± 14.7 years; 64.9% women; mean BMI 29.4 ± 6.3 kg/m2). SVT was …

AdultMalemedicine.medical_specialtySuperficial vein thrombosismedicine.drug_classDeep veinLow molecular weight heparinHemorrhage030204 cardiovascular system & hematology030230 surgeryFondaparinuxVaricose Veins03 medical and health sciences0302 clinical medicineRecurrenceRisk FactorsmedicineHumansProspective StudiesAgedAged 80 and overVenous Thrombosisbusiness.industryHazard ratioLeg UlcerAnticoagulantsHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisPulmonary embolismSurgeryVenous thrombosismedicine.anatomical_structureTreatment OutcomeFondaparinuxLower ExtremityVenous InsufficiencySurgeryFemaleCardiology and Cardiovascular MedicinebusinessPulmonary EmbolismStockings Compressionmedicine.drugFactor Xa InhibitorsEuropean journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
researchProduct

Long-Term Results of Internal Urethrotomy

1996

AbstractPurpose: A retrospective analysis was done of long-term results of internal urethrotomy to evaluate risk factors of stricture recurrence.Materials and Methods: Followup studies were performed of 937 patients with urethral strictures treated with internal urethrotomy. Of the patients 357 were treated at Mainz University between 1977 and 1989 (mean followup 4.6 years) and 580 were treated at Bonn University between 1974 and 1986 (mean followup 3.2 years).Results: Strictures recurred in 96 of 357 (26.9 percent) and 260 of 580 (44.8 percent) patients, respectively. Risk factors for recurrence were etiology (post-transurethral resection and inflammation), stricture longer than 1 cm. and …

AdultMalemedicine.medical_specialtyTime FactorsAdolescentUrethrotomyUrologyUrinary systemUrethroplastymedicine.medical_treatmentRecurrenceRisk FactorsHumansMedicineIn patientRisk factorInternal urethrotomyAgedRetrospective StudiesAged 80 and overUrethral Stricturebusiness.industryLong term resultsMiddle AgedSurgeryEtiologybusinessFollow-Up StudiesJournal of Urology
researchProduct

Duration of immunosuppressive therapy in autoimmune hepatitis

2001

AdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classmedicine.medical_treatmentMEDLINEAutoimmune hepatitisGastroenterologyRemission inductionRecurrenceInternal medicinemedicineHumansChildAgedAutoimmune diseaseHepatitisChemotherapyHepatologybusiness.industryRemission InductionMiddle Agedmedicine.diseaseHepatitis AutoimmuneImmunologyCorticosteroidFemalebusinessImmunosuppressive AgentsJournal of Hepatology
researchProduct

Recurrence rate of odontogenic keratocyst treated by enucleation and peripheral ostectomy: Retrospective case series with up to 12 years of follow-up

2018

Background Odontogenic keratocysts have been reported with high recurrence rates in the literature so various treatment modalities from simple enucleation to resection have been performed to achieve the cure. The purpose of this retrospective study was to investigate the recurrence rate of odontogenic keratocysts (OKCs) treated by enucleation and peripheral ostectomy. Material and Methods An electronic search of the database of the Hacettepe University, Faculty of Medicine, Department of Pathology, was undertaken to identify patients histologically diagnosed with OKCs treated at Department of Oral and Maxillofacial Surgery between 2001 and 2015. Results In total, 81 patients were studied. T…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.medical_treatmentOral Surgical ProceduresEnucleationOral Surgical ProceduresOsteotomyLesionYoung Adult03 medical and health sciences0302 clinical medicineRecurrencemedicineHumansOstectomyKeratocystGeneral DentistryAgedRetrospective StudiesAged 80 and overOral Medicine and Pathologybusiness.industryResearchRetrospective cohort study030206 dentistryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]OsteotomySurgeryOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASOdontogenic CystsOral and maxillofacial surgeryFemaleSurgerymedicine.symptombusinessFollow-Up StudiesMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Oncological outcome after MRI-based selection for neoadjuvant chemoradiotherapy in the OCUM Rectal Cancer Trial

2018

Abstract Background It is not clear whether all patients with rectal cancer need chemoradiotherapy. A restrictive use of neoadjuvant chemoradiotherapy (nCRT) based on MRI findings for rectal cancer was investigated in this study. Methods This prospective multicentre observational study included patients with stage cT2–4 rectal cancer, with any cN and cM0 status. Carcinomas in the middle and lower third that were 1 mm or less from the mesorectal fascia, all cT4 tumours, and all cT3 tumours of the lower third were classified as high risk, and these patients received nCRT followed by total mesorectal excision (TME). All other carcinomas with a minimum distance of more than 1 mm from the mesore…

AdultMalemedicine.medical_specialtyTime FactorsColorectal cancermedicine.medical_treatment030230 surgeryDisease-Free Survival03 medical and health sciences0302 clinical medicineCarcinomamedicineHumansProspective StudiesStage (cooking)Prospective cohort studyNeoadjuvant therapyAgedNeoplasm StagingAged 80 and overRectal Neoplasmsbusiness.industryIncidenceIncidence (epidemiology)ChemoradiotherapyMiddle Agedmedicine.diseaseMagnetic Resonance ImagingTotal mesorectal excisionNeoadjuvant TherapyEuropeSurvival RateTreatment Outcome030220 oncology & carcinogenesisFemaleSurgeryRadiologyNeoplasm Recurrence LocalbusinessChemoradiotherapyFollow-Up StudiesBritish Journal of Surgery
researchProduct

Prognostic Factors Determining Long-Term Survival in Well-Differentiated Thyroid Cancer: An Analysis of Four Hundred Eighty-Four Patients Undergoing …

2003

Identification of the prognostic factors relevant for long-term survival in differentiated thyroid cancer in a homogenously treated patient cohort in order to allow a better initial risk stratification.Four hundred eighty-four (358 females/126 males) patients with differentiated thyroid cancer (330 papillary [68.2%]; 154 follicular [31.8%]) were included. Inclusion criteria consisted of treatment with a uniform therapy scheme and continuous aftercare in the same institution. Initial diagnosis was between 1975-1995 (age at diagnosis, 14-84 years, median, 49.7). Tumor stage: pT1, n = 92; pT2, 211; pT3, 58; pT4, 123. Low-risk:or=pT3 NX M0, 331; high-risk pT4 and/or M1, 153. After thyroidectomy…

AdultMalemedicine.medical_specialtyTime FactorsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentEndocrinologyRecurrenceCause of DeathInternal medicineAdenocarcinoma FollicularFollicular phaseLong term survivalmedicineHumansSurvivorsThyroid NeoplasmsThyroid cancerAgedNeoplasm StagingRetrospective StudiesCause of deathAged 80 and overbusiness.industryWell-Differentiated Thyroid CancerThyroidectomyRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryAdenocarcinoma PapillaryCohortFemalebusinessFollow-Up StudiesThyroid
researchProduct

Prognostic Value of a Comprehensive Cardiac Magnetic Resonance Assessment Soon After a First ST-Segment Elevation Myocardial Infarction

2009

ObjectivesTo evaluate the prognostic value of a comprehensive cardiac magnetic resonance (CMR) assessment soon after a first ST-segment elevation myocardial infarction (STEMI).BackgroundCMR allows for a simultaneous assessment of wall motion abnormalities (WMA), WMA with low-dose dobutamine (WMA-dobutamine), microvascular obstruction, and transmural necrosis. This approach has been proven to be useful to predict late systolic recovery soon after STEMI. Its prognostic value and the relative prognostic weight of these indexes are not well-defined.MethodsWe studied 214 consecutive patients with a first STEMI treated with thrombolytic therapy or primary angioplasty discharged from hospital. In …

AdultMalemedicine.medical_specialtyTime FactorsMagnetic Resonance Imaging CineInfarctionKaplan-Meier EstimateRisk Assessmentcardiac magnetic resonanceNecrosisPredictive Value of TestsRecurrenceRisk FactorsDobutamineInternal medicinemedicineHumansThrombolytic TherapyRadiology Nuclear Medicine and imagingcardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryAgedProportional Hazards ModelsHeart Failurebusiness.industryMyocardiumAdrenergic beta-AgonistsMiddle Agedmedicine.diseaseCoronary VesselsMyocardial ContractionTreatment Outcomemyocardial infarctionRadiology Nuclear Medicine and imagingHeart failureMicrovesselscardiovascular systemCardiologyMyocardial infarction complicationsFemaleDobutamineprognosisMyocardial infarction diagnosisCardiology and Cardiovascular MedicinebusinessTIMIMacemedicine.drugJACC: Cardiovascular Imaging
researchProduct

[Inferior vena cava malformations and deep venous thrombosis].

2006

We carried out a prospective study of 116 patients under 50 years of age who had deep venous thrombosis of the lower extremities to determine whether the presence of congenital anomaly of the inferior vena cava (IVC) was a risk factor for the disease. All patients were investigated by Doppler echography. Some 37 patients who had iliac vein occlusion also underwent phlebography. In 10 patients in whom the IVC was difficult to image, magnetic resonance angiography or computerized axial tomography was carried out. In all patients, studies of antithrombin, protein C and protein S deficiency, factor V Leiden, prothrombin G20210A, antiphospholipid antibodies, and acquired risk factors were also p…

AdultMalemedicine.medical_specialtyTime FactorsPopliteal VeinFemoral veinVena Cava InferiorIliac VeinInferior vena cavaRecurrenceRisk FactorsmedicineFactor V LeidenConfidence IntervalsHumansProtein S deficiencyProspective StudiesVenous ThrombosisLegbusiness.industryAnticoagulantsUltrasonography DopplerGeneral MedicinePhlebographyFemoral VeinMiddle Agedmedicine.diseaseThrombosisVein occlusionSurgeryVenous thrombosisTreatment Outcomemedicine.veincardiovascular systemProthrombin G20210AFemaleRadiologybusinessTomography X-Ray ComputedMagnetic Resonance AngiographyFollow-Up StudiesRevista espanola de cardiologia
researchProduct

Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic …

2007

SummaryTreatment of relapsed or refractory autoimmune mediated haemolytic syndromes, such as autoimmune haemolytic anaemia (AIHA) and thrombotic thrombocytopenic purpura (TTP), represents a therapeutic challenge. Here we report on our experience with the monoclonal anti-CD20 antibody rituximab (R) compared to standard treatment in these diseases. Patients with non-familialTTP orAIHA and no underlying malignancy were included in our analysis. Safety and efficacy of R-treatment were compared to results obtained in standard treatment approaches. Altogether, 27 patients were analyzed, comprising 15 patients withTTP and 12 patients with AIHA. The patients’ average age at the time of diagnosis wa…

AdultMalemedicine.medical_specialtyTime FactorsThrombotic thrombocytopenic purpuraSalvage therapyGastroenterologyDisease-Free SurvivalAntibodies Monoclonal Murine-DerivedPharmacotherapyRefractoryRecurrenceMedian follow-upGermanyhemic and lymphatic diseasesInternal medicinemedicineHumansImmunologic FactorsProgression-free survivalAgedRetrospective StudiesSalvage TherapyPurpura Thrombocytopenic Idiopathicbusiness.industryStandard treatmentAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeDrug Therapy CombinationFemaleRituximabAnemia Hemolytic AutoimmuneRituximabbusinessFollow-Up Studiesmedicine.drugThrombosis and Haemostasis
researchProduct

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell glo…

2011

Abstract Previous randomized graft-versus-host disease (GVHD)-prophylaxis trials have failed to demonstrate reduced incidence and severity of chronic GVHD (cGVHD). Here we reanalyzed and updated a randomized phase 3 trial comparing standard GVHD prophylaxis with or without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients receiving myeloablative conditioning before transplantation from unrelated donors. The cumulative incidence of extensive cGVHD after 3 years was 12.2% in the ATG-F group versus 45.0% in the control group (P < .0001). The 3-year cumulative incidence of relapse and of nonrelapse mortality was 32.6% and 19.4% in the ATG-F group and 28.2% and 33.5% in the contr…

AdultMalemedicine.medical_specialtyTime FactorsTransplantation ConditioningAdolescentmedicine.medical_treatmentImmunologyMedizinGraft vs Host DiseaseHematopoietic stem cell transplantationBiochemistryGastroenterologyDisease-Free Survivallaw.inventionRandomized controlled triallawRecurrenceInternal medicinemedicineHumansTransplantation HomologousCumulative incidenceSurvival rateAntilymphocyte SerumImmunosuppression Therapybusiness.industryIncidence (epidemiology)Hazard ratioHematopoietic Stem Cell TransplantationCell BiologyHematologyMiddle Agedmedicine.diseaseSurgeryTransplantationSurvival RateGraft-versus-host diseaseMethotrexateHematologic NeoplasmsChronic DiseaseCyclosporineFemalebusinessImmunosuppressive AgentsBlood
researchProduct